| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $10.2M | — |
| Cost of Revenue | $603K | — |
| R&D Expense | $1.9M | -52.3% |
| SG&A Expense | $29.1M | +262.9% |
| Operating Income | -$22.7M | -91.1% |
| Net Income | -$20.7M | -41.2% |
| EPS (Basic) | -$1.17 | +42.1% |
| EPS (Diluted) | -$1.18 | +41.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $66.0M | +36.0% |
| Accounts Receivable | $4.2M | — |
| Inventory | $5.1M | +732.9% |
| Current Assets | $79.0M | +57.2% |
| Total Assets | $79.7M | +57.1% |
| Current Liabilities | $9.1M | +172.5% |
| Total Liabilities | $17.2M | +85.5% |
| Stockholders' Equity |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$20.4M | -162.8% |
| Capital Expenditures | $293K | +999.2% |
| Investing Cash Flow | -$293K | -999.2% |
| Financing Cash Flow | $38.2M | -30.3% |
| Free Cash Flow | -$20.7M | -165.7% |
| $62.5M |
| +50.8% |